FDA Warns Of Potential Dangers Of Controversial Multiple Sclerosis Treatment - RTT News

Injectables like Teva's Copaxone, Biogen Idec's Avonex and Tysabri, and Merck Serono's Rebif and oral drug Gilenya, developed by Novartis AG, are some of the approved treatments for multiple sclerosis.

Merck KGaA Declines to Four-Month Low as Profit Declines - Bloomberg

Merck’s Rebif multiple sclerosis infusion treatment, the company’s top-selling product, faces increased competition from newer therapies. In June, the drugmaker dropped development of a multiple sclerosis pill, cladribine, which had been its ...

Merck KGaA's Erbitux Faces Hurdle - Analyst Blog - NASDAQ

We currently have a Zacks #2 Rank (short-term Buy rating) on Merck KGaA. Despite the negative data, we believe that Erbitux along with Rebif and the Merck Millipore division will help drive growth at Merck KGaA.

Researchers finally publish report on JC virus (video) - Examiner

I'd changed from Rebif since I'd been having new difficulties with my MS,” she said. “The thing is, it appears as if this isn't working either so I'd been going through different options with my neuro and had entertained Tysabri; but was still scared ...

Earnings Miss at Merck KGaA - Analyst Blog - NASDAQ

Rebif (up 2.7%) and Erbitux (up 1.3%) also contributed to the segment's growth. The Consumer Health Care division's revenues declined 7.3%, primarily due to lower sales. Merck KGaA's Merck Millipore division's revenue went up 7.8% from the year ...

MS blog follow-up: immune-modulating therapies - Patriot-News Blogs

But I'll do my best: • Inferons: primarily treat RRMS (Avonex, Betaseron, Extavia, Rebif). Basically, interferons are proteins released in response to pathogens, triggering the immune system to become protective and defensive. • Fingolimod ...

5 Fantastic Healthcare Dividends For The Income Investor - Seekingalpha.com

Some of the company's products include BeneFIX, Enbrel, Genotropin, Geodon, Prevnar/Prevenar, Rebif, ReFacto AF, Revatio, Xalatan, Xyntha, and Zyvox. Pfizer currently yields 3.9% ($0.88) and trades at a P/E ratio of 18.18, making the stock affordable for ...

Earnings Miss at Merck KGaA - Zacks.com

Rebif (up 2.7%) and Erbitux (up 1.3%) also contributed to the segment’s growth. The Consumer Health Care division’s revenues declined 7.3%, primarily due to lower sales. Merck KGaA’s Merck Millipore division’s revenue went up 7.8% from the year-ago ...

Clean energy project using carbon dioxide a breath of fresh air - The Australian

Rebif; the anti-cancer drug Erbitux; a new vaccination for hepatitis B; a method for bone marrow transplants from mismatched donors; a method for distinguishing between malignant and benign tumours; varieties of agricultural crops including protein-rich ...

Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth … - Yahoo Finance

NEW YORK, May 10, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: http://www.reportlinker.com/p0850351/Autoimmune-Disorders-Therapeutics-Market-to-2017---Launch-of-Gilenya-and ...